Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23360639 | 1.00 | PARP1 (0.59) | PARP1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL6980865 | 0.85 | KDM4E (0.61) | PARP1MEN1KMT2APOLBGAA | |
| SCHEMBL23360426 | 0.83 | TNKS (0.53) | PARP1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL23107983 | 0.81 | USP30 (0.64) | PARP1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL2071421 | 0.80 | TP53 (0.52) | PARP1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL8063381 | 0.79 | USP30 (0.68) | PARP1L3MBTL1POLBUSP30LMNA | |
| SCHEMBL19284734 | 0.79 | GPR119 (0.54) | POLBGAAATMTHRBMAPT | |
| SCHEMBL29862391 | 0.79 | USP30 (0.51) | PARP1POLBGAAATMUSP30 | |
| SCHEMBL28833991 | 0.79 | USP30 (0.51) | PARP1POLBGAAATMUSP30 | |
| SCHEMBL28833992 | 0.79 | USP30 (0.51) | PARP1POLBGAAATMUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | PARP1 275/4885MEN1 2004/4885KMT2A 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.